0
0 (0%)
Intellipharmaceutics International Inc. [IPCI]
Source:
Company Overview
Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs.
| Country | United States |
| Headquarters | toronto |
| Phone Number | (416) 798-3001 |
| Industry | manufacturing |
| CEO | Dr. Isa Odidi |
| Website | www.intellipharmaceutics.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0 |
| Operating Profit | $-4.2 |
| Net Income | $-5.1 |
| Net Cash | $0.6 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -187.7% |
| Profit as % of Stockholder Equity | 63.1% |
Management Effectiveness
| Return on Equity | 63.1% |
| Return on Assets | -245.4% |
| Turnover Ratio | |
| EBITA | $-3.9 |
Balance Sheet and Cash Flow Measures
| Total Assets | $2.1 |
| Total Liabilities | $10.3 |
| Operating Cash Flow | $-2.5 |
| Investing Cash Flow | $0 |
| Financing Cash Flow | $3 |
